kidney issues with tirzepatide Protecting kidneys is a crucial part of managing Type 2 Diabetes. Recent evidence from the SURPASS-CVOT study suggests that may help reduce the risk of complications, slow kidney function decline, Join a trial on tirzepatide

Inside, we detail their comparative benefits, side effects, and more.

and in July 2024, the FDA approved Kisunla (donanemab) for early symptomatic Alzheimers, based on evidence of reduced clinical decline and a limitedduration regimen tied to amyloid plaque removal

"I don't count calories anymore

Obesity and type 2 diabetes mellitus (T2D) increase the risk of kidney disease

Weight Management providing Microdosing for GLP-1s services to Baton Rouge, LA

In the first comparative effectiveness study of tirzepatide (Mounjaro) and semaglutide (Ozempic) for weight loss using real-world data, Truveta Research found that patients with overweight or obesity taking tirzepatide were three times more likely to achieve 15% weight loss than those taking semaglutide (Ozempic)